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High CD3 and ICOS and low TIM-3 
expression predict favourable 
survival in resected oesophageal 
squamous cell carcinoma
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With the increasing oncological potential of immunotherapy, several immune checkpoint modulators 
are being investigated. The value of immune markers, including programmed cell death ligand-1, 
programmed cell death-1 (PD-1), inducible co-stimulator (ICOS), lymphocyte activation gene-3, 
T-cell immunoglobulin, and mucin-dominant containing-3 (TIM-3), is not well known. Using tissue 
microarrays of 396 patients who underwent surgery for oesophageal squamous cell carcinoma (ESCC), 
infiltrated T-cell subsets (CD3, CD8, and Foxp3) and checkpoint protein expression were scored. With a 
median follow-up of 24.8 months, CD3+ TIL subsets (50.0%) had longer median recurrence-free survival 
(RFS, 55.0 vs 21.4 months) and overall survival (OS, 77.7 vs 35.8 months). Patients with high ICOS 
expression (46.5%) had longer median RFS (53.9 vs 25.3 months) and OS (88.8 vs 36.9 months). For 
PD-1, RFS (hazard ratio [HR] 0.67) and OS (HR 0.66) were significantly longer in the high-expression 
group (45.2%). In the multivariate analysis, high TIM-3 expression (50.8%) had a significant relationship 
with shorter RFS (HR = 1.52) and OS (HR = 1.60). High CD3+ TIL and T-cell ICOS expression were 
associated with favourable prognosis, whereas high TIM-3 expression suggested a poor prognosis. Our 
findings may confer new insights to improve ESCC outcomes beyond the application of PD-1 blockade.
Oesophageal cancer is the sixth leading cause of global cancer-related death1. Despite developments in surgi-
cal and radiation techniques and chemotherapeutic agents, the prognosis of advanced oesophageal squamous 
cell carcinoma (ESCC) is generally poor, with a <35% 5-year survival rate2. There are two types of oesophageal 
cancer: ESCC and oesophageal adenocarcinoma. In Eastern Asia, >90% of oesophageal cancer cases are ESCC, 
with growing recognition that ESCC and oesophageal adenocarcinoma have distinct phenotypes, aetiologies, 
and pathogeneses3. The seventh and upcoming eighth edition cancer staging systems of the American Joint 
Committee on Cancer (AJCC) assign separate guidelines for staging these two cancer types4.
Immune escape occurs when cancer cells evade the host immune system. The interaction between pro-
grammed cell death ligand-1 (PD-L1) and programmed cell death protein-1 (PD-1) is a common and important 
immune-evading mechanism in many cancer types and blocking this interaction has emerged as a breakthrough 
in cancer therapy5. Since late 2016, PD-1 inhibitors have been approved for melanoma, non-small cell lung cancer, 
renal cell carcinoma, and head and neck cancer by the U.S. Food and Drug Administration; compared with old 
cytotoxic agents, PD-1 inhibitors have superior efficacy with an improved safety profile in various tumour types6. 
These checkpoint inhibitors have been adapted to daily clinical practice, dramatically changing malignant tumour 
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treatment. Clinical trials with pembrolizumab and nivolumab are ongoing and include almost every tumour type 
from solid tumours to haematologic malignancies and from neoadjuvant and adjuvant to the palliative setting7.
Besides the PD-1/PD-L1 pathway, agents modulating other checkpoints, including inducible co-stimulator 
(ICOS), lymphocyte activation gene-3 (LAG-3), T-cell immunoglobulin and mucin-dominant containing-3 
(TIM-3), and T-cell immunoreceptor with Ig and ITIM domains (TIGIT), are actively under development8–10. 
With PD-1/PD-L1 blockade as a backbone, combination approaches with these immune checkpoint modulators 
appear promising; this strategy may help overcome resistance to PD-1/PD-L1 inhibitors. Despite this approach, 
studies evaluating the prognostic and predictive impacts in each cancer type have produced inconsistent 
results11,12. The roles of PD-1, PD-L1, and other immune checkpoints in various cancer types remain unknown. 
Moreover, the clinical implications of various immune receptors in ESCC, including PD-1, PD-L1, LAG-3, TIM-
3, and TIGIT, remain undefined.
Here, we investigated the distribution and frequency of CD3+/CD8+ T-cells, regulatory T-cells, and other 
immune checkpoints, including PD-L1, PD-1, ICOS, LAG-3, and TIM-3, in surgically resected ESCC and also 
determined their prognostic value in identifying potential therapeutic targets.
Results
Baseline characteristics. Overall, 407 patients who underwent surgical resection for ESCC were identified. 
Eleven cases were excluded due to incomplete staining, and 396 eligible ESCC tumour samples were assessed. 
They were evaluated for PD-L1 expression (on both tumour and immune cells) and CD3, CD8, Foxp3, ICOS, 
LAG-3, and TIM-3 expression (Supplementary Fig. 1). Table 1 shows the patients’ baseline characteristics. The 
median age was 64 years (range: 41–83 years); most patients were male (93.4%) and were current or former 
smokers (73.5%). The percentages of patients in stage I, II, III, and IV at surgery were 21.2%, 45.7%, 30.0%, and 
3.0%, respectively. None of the patients received neoadjuvant treatment. During the median follow-up period of 
24.8 (range 0.5–210) months, 129 (32.6%) patients experienced recurrence, and 181 (45.7%) deaths occurred. The 
5-year overall survival (OS) rate was 44.9% in the total population.
Prognostic impact of CD3+, CD8+, and Foxp3+ T-cell lymphocyte density. Patients were grouped 
into low- and high-frequency groups based on tumour-infiltrating lymphocytes (TILs) according to a median 
value of 252/4HPFs for CD3+ TILs, 96/4HPFs for CD8+ TILs, and 0/4HPFs for Foxp3+ TILs. The association 
between the frequency of CD3+, CD8+, and Foxp3+ T-cell lymphocytes and the clinicopathological character-
istics of patients are shown in Supplementary Tables 1–3, respectively. High densities of both CD3+ TIL and 
FoxP3 + TIL were associated with high pathologic T and TNM stage (Supplementary Tables 1 and 3). The 
high-frequency CD3+ TILs group (n = 198, 50.0%) had a significant longer RFS (hazard ratio [HR] = 0.61, 95% 
confidence interval [CI]: 0.46–0.81, P = 0.0005) and OS (HR = 0.59, 95% CI: 0.44–0.80, P = 0.0005) than the low 
frequency CD3+ TILs group (Fig. 1A,B). The high- and low-frequency CD3+ TILs groups had medians of 55.0 
and 21.4 months for RFS and medians of 77.7 and 35.8 months for OS, respectively. After adjusting for age, sex, 
smoking status, and various T-cell marker expression levels, multivariate analysis demonstrated a low risk of 
disease relapse (HR = 0.57, 95% CI: 0.41–0.78, P < 0.001) and death (HR = 0.52, 95% CI: 0.37–0.74, P < 0.001) in 
the high-frequency CD3+ TILs group (Tables 2 and 3). However, there was no prognostic association between the 
density of CD8+ TILs or Foxp3+ TILs and RFS or OS (Fig. 1C–F).
Prognostic implication of ICOS, LAG-3, PD-1, and TIM-3 expression in immune cells. We inves-
tigated the expression of immune receptors (ICOS, LAG-3, PD-1, and TIM-3) in immune cells. The median val-
ues of ICOS, LAG-3, and PD-1 expression in immune cells were 0/4HPFs, 22/4HPFs, and 0/4HPFs, respectively. 
Given the abundance of TIM-3 expression, the proportion of TIM-3-positive immune cells was not numbered 
as the cell count/HPF but scored as the percentage of stained cells in the total immune cells. Because the median 
percentage of TIM-3 expression was 0%, TIM-3 expression of ≥1% was defined as high density. The association 
between the expression of ICOS, LAG-3, PD-1, and TIM-3 and clinicopathological characteristics of patients 
are shown in Supplementary Tables 4–7, respectively. Fisher’s exact test indicated that low ICOS expression was 
associated with smoking. Additionally, low pathologic T and pathologic TNM stage was related to high LAG-3 
expression. There was no significant association between PD-1 expression and the clinical characteristics. In the 
survival analysis of these markers, patients with high ICOS expression (n = 184, 46.5%) demonstrated a signifi-
cantly longer RFS (HR = 0.72, 95% CI: 0.55–0.95, P = 0.021) and OS (HR = 0.67, 95% CI: 0.50–0.89, P = 0.007) 
compared to that in patients with low ICOS expression (Fig. 2A,B). The high and low ICOS groups had medians 
of 53.9 and 25.3 months, respectively, for RFS and medians of 88.8 and 36.9 months, respectively, for OS. Similar 
results were observed in uni- and multivariate Cox analyses comparing high vs low ICOS expression (Tables 2 
and 3; HR = 0.67, 95% CI: 0.50–0.89, P = 0.007 for recurrence; and HR = 0.61, 95% CI: 0.45–0.85, P = 0.003 
for survival, all in multivariate analysis). LAG-3 expression was not associated with RFS and OS duration in 
either Kaplan-Meier or uni- and multivariate analyses (Fig. 2C,D, and Table 2). Regarding PD-1 expression, 
RFS (HR = 0.67, 95% CI: 0.50–0.88, P = 0.004) and OS (HR = 0.66, 95% CI: 0.49–0.88, P = 0.006) were signif-
icantly better in the high-expression group (n = 179) than in the low-expression group (n = 217) (Fig. 2E,F). 
While there was a trend toward better survival in patients with high PD-1 expression, Cox regression analysis 
indicated that associations between survival and PD-1 expression were non-significant (Tables 2 and 3). TIM-3 
expression had no prognostic value for RFS and OS in the Kaplan-Meier analysis (Fig. 2G,H). However, in the 
uni- and multivariate analyses using Cox regression, high TIM-3 expression (n = 201, 50.8%) was associated with 
a higher probability of recurrence (HR = 1.52, 95% CI: 1.10–2.10, P = 0.011 in multivariate analysis) and death 
(HR = 1.60, 95% CI: 1.13–2.27, P = 0.008 in multivariate analysis) (Tables 2 and 3). To refer our finding to an 
independent patient cohort, we applied gene expression to The Cancer Genome Atlas (TCGA) ESCC samples 
regarding TIM-3 (n = 85, Supplementary Fig. 2). At first, mRNA expression data of hepatitis A virus cellular 
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receptor 2 (HAVCR2) gene, which encodes the TIM-3 protein in ESCC, were obtained from the Genomic Data 
Commons Data Portal (CDC) in TCGA and OncoLnc. OncoLnc is a resource to link TCGA survival data to 
mRNA, miRNA, or lncRNA expression (available at http://www.oncolnc.org)13,14. There was no difference in 
OS between the high and low HAVCR2 mRNA expressions (median OS, 42.1 and 18.9 months, respectively, 
HR = 0.67, 95% CI 0.3–1.48, P = 0.32).
PD-L1 immunohistochemistry. Among 396 patients, 101 (25.5%), 89 (22.5%), 60 (15.7%), 33 (8.3%), 
and 14 (3.5%) had positive IHC staining of PD-L1 in ≥1%, ≥5%, ≥10%, ≥25%, and ≥50% of tumour cells, 
respectively. For immune cells, 189 (47.7%), 141 (35.6%), 97 (24.4%), 44 (11.1%), and 21 (5.3%) patients had 
≥1%, ≥5%, ≥10%, ≥25%, and ≥50% of cells showing PD-L1 IHC staining, respectively. Seventy-four percent of 
tumour cells and 52% of immune cells did not express PD-L1 (Supplementary Fig. 3). With a 5% cut-off point, no 
significant correlation was observed between T-cell frequency and age, sex, tumour location, smoking status, and 
TNM stage. However, higher PD-L1 expression in tumour cells was related to a higher N stage (Supplementary 
Tables 8 and 9).
Characteristics N (%)
Age, years
Median (range) 64 (41–83)
Sex
Male 370 (93.4%)
Female 26 (6.6%)
Location
Upper 24 (6.1%)
Middle 84 (21.2%)
Lower 288 (72.7%)
Tumor grade
Well 72 (18.2%)
Moderate 261 (65.9%)
Poorly 63 (15.9%)
Smoking statusa
Never smoker 103 (26.0%)
Former smoker 100 (25.2%)
Current smoker 193 (48.7%)
Smoking dosage, pack-years
Median 25
Range 0–100
pT stage
T1 119 (30.1%)
T2 81 (20.5%)
T3 181 (45.7%)
T4 15 (3.8%)
pN stage
N0 202 (51.0%)
N1 165 (41.7%)
N2 20 (5.1%)
N3 9 (2.3%)
pTNM stage (AJCC 7th edition)
I 84 (21.2%)
II 181 (45.7%)
III 119 (30.0%)
IV 12 (3.0%)
Adjuvant therapy
Yes 346 (87.4%)
No 50 (12.6%)
Table 1. Baseline Characteristics in 396 ESCC Patients. aNever smokers, a lifetime smoking dose of fewer than 
100 cigarettes; former smokers, those who have stopped smoking for more than 1 year; current smokers, those 
who currently smoke or have quit for less than 1 year. AJCC, American Joint Committee on Cancer; ESCC, 
oesophageal squamous cell carcinoma.
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Prognostic impact of PD-L1 expression on tumour and immune cells. PD-L1 expression on 
tumour and immune cells with various cut-offs (1%, 5%, 10%, 25%, and 50%) were evaluated among 396 samples 
and analysed in relation to the survival data (Fig. 3). The median PD-L1 expression rate was 0% in both tumour 
and immune cells, while the corresponding means were 5.6% and 8.0%, respectively. Even after incorporating 
various cut-off points in tumour and immune cells, our data indicated no significant correlation between PD-L1 
expression and RFS and OS. Multivariate Cox analysis showed similar results (Tables 2 and 3). Median RFS and 
OS of patients with PD-L1 expression in ≥50% immune cells (n = 21, 5.3%) were numerically greater than those 
in patients with PD-L1 expression in <50% of cells (median RFS: 111.1 vs 30.7 months, P = 0.355, median OS: 
111.1 vs 42.3 months, P = 0.367). However, this difference was not statistically significant.
Relationships among expression of various immune markers. Overall, the median expression 
levels of FoxP3, ICOS, PD-1, and PD-L1 were 0, and any expression from these markers was considered as a 
“higher expression”. Moreover, the expression of one immune marker has close associations with other mark-
ers (Supplementary Table 10). After performing Spearman’s rank correlation analysis, CD8+ TIL expression 
was related with LAG-3, PD-1, TIM-3, and PD-L1 expression in immune cells (P < 0.001, respectively). Two 
immune markers, CD3 and ICOS, that displayed a prognostic role in this study were linked (r = 0.128, P = 0.011). 
However, no significant association was present between CD8 and ICOS expression or between ICOS and LAG-3 
expression.
Figure 1. Kaplan-Meier analysis for probability of recurrence (A,C,E) and survival (B,D,F) based on the 
density of tumour-infiltrating lymphocytes. CD3 (A,B), CD8 (C,D), and Foxp3 (E,F).TIL, tumour-infiltrating 
lymphocyte.
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Combination of CD3+ TIL with ICOS, PD-1, and TIM-3 expression. We classified ESCC subjects 
into four subgroups based on CD3+ TIL positivity and ICOS expression, and the same method was applied for 
CD3 with PD-1 and CD3 with TIM-3, as these were proposed to have a prognostic impact in the current analy-
sis. The Kaplan-Meier analysis revealed significant differences in RFS among these four types in each subgroup 
(Supplementary Fig. 4). Consistent with the strong prognostic characteristics of ICOS and PD-1, CD3+ subgroups 
with positive ICOS or PD-1 expression showed the longest RFS (median: 88.8 and 58.0 months, respectively) 
compared with subgroups that were CD3+/ICOS- or CD3+/PD-1- (median: 18.6 and 17.6 months, respectively). 
Furthermore, consistent with the poor prognostic profile of TIM-3, subgroups that were CD3+/TIM-3− demon-
strated the longest RFS (median: 59.7 vs 3.5 months in CD3−/TIM-3−). However, these correlations with RFS did 
not translate into OS.
Discussion
ESCC is one of the most aggressive cancers. Definitive surgical therapy, including oesophagectomy, is considered 
a standard treatment for resectable diseases; however, >50% of patients undergo local recurrence and/or distant 
metastasis15,16. Even with recent improvements in sequencing techniques and precision medicine, molecularly 
targeted therapy has a limited role. Furthermore, traditional cytotoxic agents have not demonstrated progress 
in the last decade. Therefore, ESCC prognosis is dismal, with a high unmet need. In other cancer types such as 
lung cancer, immune checkpoint inhibitors, represented by PD-1/PD-L1 blockade, have recently shown prom-
ising efficacy in treating advanced/metastatic ESCC17,18. In a clinical trial, the objective response rate of 17% 
and a median OS of 10.8 months appear to be encouraging considering the heavily treated characteristics in the 
study population18. Despite the impressive outcomes of PD-1/PD-L1 inhibitory cancer immunotherapy, efficacy 
is suboptimal, and most patients with many tumour types do not show a response19. Thus, the focus has shifted to 
targeting alternative immune checkpoints receptors.
Combining two or more anti-tumour drugs for improving cancer treatment is not a new concept in oncology, 
and it is also valid in the immuno-oncology era20. Combination therapy involving PD-1/PD-L1 inhibitors with 
other immune checkpoint modulators has been considered an important strategy to overcome primary and sec-
ondary resistances to PD-1/PD-L1 blockade21. Several immune modulators are being investigated in pre-clinical 
models and clinical trials; however, our understanding of these checkpoints is incomplete, especially in ESCC. 
Univariate analysis Multivariate analysis
Categorya HR 95% CI P value HR 95% CI P value
Age ≥60 or <60 (ref) 1.58 1.16–2.22 0.004 1.41 1.03–1.94 0.031
Sex Female ormale (ref) 0.57 0.30–1.07 0.055 0.64 0.32–1.28 0.211
Smoking
Ever-smoker 
or never-
smoker (ref)
1.38 0.99–1.91 0.053 1.48 1.07–2.06 0.019
Tumor Location
Lower or
middle or
lower (ref)
1.21
1.06
0.77–1.91
0.73–1.52
0.771
0.411
1.25
1.05
0.78–1.98
0.75–1.66
0.778
0.795
Tumor Grade
Poorly or
moderate or
well (ref)
1.29
0.94
0.68–2.45
0.47–1.89
0.435
0.863
1.30
0.85
0.77–2.65
0.84–2.45
0.556
0.846
CD3+ T-cell High orlow (ref) 0.48 0.32–0.71 <0.001 0.57 0.41–0.78 <0.001
CD8+ T-cell High orlow (ref) 1.29 0.91–1.12 0.146 1.31 0.92–1.85 0.132
Foxp3+ T-cell High orlow (ref) 1.33 0.97–1.82 0.077 1.29 0.94–1.77 0.114
ICOS+ immune cell High orlow (ref) 0.62 0.45–0.85 0.003 0.67 0.50–0.89 0.007
LAG-3+ immune cell High orlow (ref) 0.98 0.70–1.38 0.910 0.95 0.67–1.35 0.777
PD-1+ immune cell High orlow (ref) 0.78 0.57–1.07 0.129 0.77 0.56–1.06 0.112
TIM-3+ Immune cell High orlow (ref) 1.44 1.02–2.03 0.040 1.52 1.10–2.10 0.011
PD-L1+ tumor cell (5% or more) High orlow (ref) 1.16 0.83–1.62 0.391 1.18 0.85–1.65 0.325
PD-L1+ immune cell (5% or more) High orlow (ref) 0.94 0.67–1.31 0.700 0.91 0.65–1.28 0.602
Stage III, IV vs I, II High orlow (ref) 3.26 2.42–4.37 <0.001 3.06 2.30–4.05 <0.001
Table 2. Uni- and Multivariate Cox Regression Analyses Estimating the Association of Various Immune 
Markers with Recurrence. Associations determined by Cox proportional hazards regression and adjusted for 
age, sex, smoking status, and TNM stage. aDefinition of high or low for each immune marker is described in the 
main manuscript. ESCC, oesophageal squamous cell carcinoma.
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Furthermore, the expression level cut-offs, associations with clinicopathological features, and prognostic impact 
of these various checkpoints have not been established for ESCC. The PD-L1 expression level has a critical role in 
T-cell regulation, but the precise significance varies among studies and cancer types22.
We comprehensively investigated the prognostic impact of immune cell infiltration and various immune 
checkpoints, including PD-L1, PD-1, ICOS, LAG-3, and TIM-3, in resected ESCC. Additionally, the significance 
of clinical factors such as sex, age, smoking status, and TNM stage was explored. The most significant prognostic 
factor was the TNM stage (Table 2 and Supplementary Fig. 5). Given that the number of stage IV subjects was 
small, it may not have a significant impact on OS and mitigate the influence of immune markers.
Several studies report that TILs have a positive prognostic effect across various cancer types23–25. TILs have 
an important role in anticancer immune responses and the cancer immunity cycle26. However, TILs are divided 
into several subgroups based on cell surface antigen expression. Each subset has a distinct interactive function 
between the tumour and tumour microenvironments and sometimes the roles differ across cancer types27. CD3 
is a transmembrane protein that is exclusively expressed in the T-cell pedigree and thus is considered to repre-
sent a mature T-cell marker and whole tumour-infiltrating T-cells28. CD8 T-cells generally represent cytotoxic 
T-cells, and Foxp3 is the distinct transcription marker of regulatory T-cells29. Among different lymphocyte types, 
CD3-positive TILs are most significantly associated with survival across various tumours27. Consistent with pre-
vious literature on total TILs or stromal TILs in ESCC, in the present ESCC study, high CD3+ TIL density showed 
good prognostic impact, whereas CD8+ TILs and Foxp3+ TILs did not30–32. We attempted to investigate stro-
mal and intra-tumoural CD3+ or CD8+ TILs independently; however, TIL abundance made it unfeasible. One 
meta-analysis showed that CD8+ TILs were associated with good prognosis; however, it included a heterogeneous 
population of patients with oesophageal adenocarcinoma and squamous cell carcinoma33.
To our knowledge, we are the first to report ICOS, LAG-3, and TIM-3 expressions and their clinical implica-
tion in a large ESCC cohort. As expected, ICOS, LAG-3, and TIM-3 expressions were related to PD-1 expression 
on TILs, possibly indicating the feedback nature of the immune system (Supplementary Table 10).
ICOS is a surface antigen in T-cells, and its expression is low in naïve T-cells. Once ICOS is stimulated by both 
the T-cell receptor and CD28 signals, it is upregulated in activated T-cells34. Co-stimulation by ICOS and ICOS 
ligand confers an anticancer response, but ICOS signalling also engages regulatory T-cell activity induction35. 
Thus, ICOS might have a dual role in oncogenesis. The prognostic impact of ICOS expression is inconsistent 
Univariate analysis Multivariate analysis
Categorya HR 95% CI P value HR 95% CI P value
Age ≥60 or <60 (ref) 1.66 1.18–2.31 0.003 1.47 1.05–2.06 0.026
Sex Female ormale (ref) 0.60 0.30–1.17 0.131 0.69 0.32–0.70 0.313
Smoking
Ever-smoker 
or never-
smoker (ref)
1.32 0.94–1.86 0.110 1.44 1.01–2.04 0.042
Tumor Location
Lower or
middle or
lower (ref)
1.29
1.00
0.46–2.16
0.64–2.64
1.000
1.297
1.40
1.15
0.50–2.22
0.72–2.52
1.000
1.320
Tumor Grade
Poorly or
moderate or
well (ref)
1.15
1.04
0.71–1.87
0.70–1.53
0.58
0.86
1.10
0.98
0.70–1.89
0.68–1.55
0.69
0.85
CD3+ T-cell High orlow (ref) 0.48 0.32–0.71 <0.001 0.52 0.37–0.74 <0.001
CD8+ T-cell High orlow (ref) 1.38 0.97–1.99 0.078 1.38 0.96–1.98 0.087
Foxp3+ T-cell High orlow (ref) 1.29 0.93–1.79 0.133 1.29 0.93–1.80 0.132
ICOS+ immune cell High orlow (ref) 0.61 0.43–0.85 0.004 0.61 0.45–0.85 0.003
LAG-3+ immune cell High orlow (ref) 1.06 0.74–1.52 0.747 1.03 0.71–1.49 0.876
PD-1+ immune cell High orlow (ref) 0.81 0.58–1.14 0.220 0.80 0.57–1.12 0.192
TIM-3+ Immune cell High orlow (ref) 1.53 1.06–2.22 0.024 1.60 1.13–2.27 0.008
PD-L1+ tumor cell (5% or more) High orlow (ref) 0.96 0.68–1.41 0.891 1.00 0.69–1.44 0.987
PD-L1+ immune cell (5% or more) High orlow (ref) 0.76 0.52–1.10 0.146 0.73 0.50–1.07 0.106
Stage III, IV vs I, II High orlow (ref) 3.66 2.67–5.00 <0.001 3.34 2.47–4.51 <0.001
Table 3. Uni- and Multivariate Cox Regression Analyses Estimating the Association of Various Immune 
Markers with Patients’ Survival. Associations determined by Cox proportional hazards regression and adjusted 
for age, sex, smoking status, and TNM stage. aDefinition of high or low for each immune marker is described in 
the main manuscript. ESCC, oesophageal squamous cell carcinoma.
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across various tumour types (e.g., melanoma, colorectal cancer, breast cancer, gastric cancer, and renal cell car-
cinoma), and these clinical findings support the dual role of ICOS in carcinogenesis8. In our study, high ICOS 
expression in immune cells was significantly associated with longer RFS and OS in the Kaplan-Meier method 
and multivariate Cox regression model (Fig. 2 and Table 2). Our findings suggest that ICOS-expressing immune 
cells include tumour neoantigen-specific T-cells and are associated with favourable prognosis, at least in ESCC. 
However, this should be validated in an independent patient cohort and in clinical trials with ICOS-targeted 
therapies.
Despite the existence of several LAG-3-related studies, data regarding the prognostic impact of LAG-3 in most 
cancer types are limited9. Two reports on NSCLC have contradictory results36,37. Moreover, one exploratory study 
Figure 2. Kaplan-Meier analysis for probability of recurrence (A,C,E,G) and survival (B,D,F,H) based on the 
expression of each immune checkpoint. ICOS (A,B), LAG-3 (C,D), PD-1 (E,F), TIM-3 (G,H). ICOS, inducible 
co-stimulator; LAG-3, lymphocyte activation gene-3; PD-1, programmed cell death protein 1; TIM-3, T-cell 
immunoglobulin and mucin-dominant containing-3.
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showed that LAG-3 expression was associated with good prognosis in resected ESCC; however, this is inconsist-
ent with the current data38. Accordingly, the role of LAG-3 in cancer and ESCC in particular remains elusive.
As a marker of CD8+ T-cell dysfunction or exhaustion, TIM-3 is occasionally co-expressed with PD-1 in 
CD8+ T-cells in several tumours19. Moreover, TIM-3 is expressed in natural killer cells, regulatory T-cells, den-
dritic cells, B-cells, macrophages, and other myeloid cells. TIM-3 expression inhibited anti-tumour immunity by 
T-cell exhaustion, suppressed immune response from the status of innate immunity, and exhibited pro-tumour 
activity by promoting myeloid-derived suppressor cells9. Consistent with the previously known immune regu-
latory role of TIM-3 in oncogenesis, TIM-3 expression is associated with poor prognosis in several cancers39,40. 
The high probability of recurrence or death was also related to high TIM-3 expression in the present study, which 
is the first to report the prognostic impact of TIM-3 in ESCC. In several preclinical studies, blocking TIM-3 
enhanced cancer immunity by T-cell proliferation and cytokine production, as well as combination with PD-1 
blockade, also demonstrated a remarkable synergy in these models10. Additionally, many clinical trials focusing 
on targeting TIM-3 are ongoing globally41. One important issue regarding blocking TIM-3 might be related to 
their expression levels in various tumour-infiltrating immune cells. Most patients (92%, 364/396, data not shown) 
in the present study expressed TIM-3 in T-cells. Thus, based on the high frequency of TIM-3 expression and its 
demonstrated poor prognostic value, TIM-3 may be a potential target candidate in ESCC. In conjunction with 
the current role of PD-1 blocking agents in ESCC, the use of TIM-3-targeted therapy in combination with PD-1 
blockade may be a promising strategy. Although more studies are needed, our study may provide some evidence 
supporting the approach to target TIM-3 in ESCC.
Together with advances in PD-1/PD-L1 blockade, the relationship of PD-1/PD-L1 expression and its prognostic 
impact in various tumour types are gaining increased attention. Although the Kaplan-Meier method revealed that 
high PD-1 expression in TILs was associated with better RFS and OS, in Cox regression analyses, patients with high 
PD-1 expression had increased risk of relapse and death compared with those with low PD-1 expression. Considering 
the high association with PD-1 and other immune checkpoints, the overlap and diverse interaction between various 
immune checkpoints may attenuate the prognostic impact of PD-1 in ESCC (Supplementary Table 10).
Figure 3. Kaplan-Meier plots showing the prognostic value of PD-L1 staining on tumour cell or immune cell, 
using different pre-specified cut-offs (1, 5, 10, 25, and 50%). (A–J) PD-L1 expression in tumour cell; (K–T) 
PD-L1 expression in immune cell; (A–E,K–O) recurrence-free survival; (F–J, P–T) overall survival.
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Regarding PD-L1, 25.5% (101/396) of patients showed PD-L1 expression in ≥1% of tumour cells and in 47.7% 
(189/396) of immune cells (Supplementary Fig. 3). We used various cut-offs of PD-L1 expression in tumour or 
immune cells to determine associations with prognosis, but we did not identify any meaningful associations with 
recurrence or survival. Because blocking PD-1/PD-L1 has gained much attention, several studies have investi-
gated the prognostic role of PD-L1 expression in ESCC. However, these studies presented inconsistent results30. 
Some studies reported that PD-L1 expression was associated with poor prognosis, but another study indicated it 
was not associated with poor prognosis. A meta-analysis showed a positive but statistically non-significant trend 
in prognosis with PD-L1 expression42. In our study, there were no clinically significant relationships between sur-
vival and PD-L1 expression in tumour or immune cells. These conflicting results might derive from differences in 
the patient population, staining method and antibodies, and definition of PD-L1 positivity. Thus, heterogeneity 
in the prognostic role of PD-L1 has been observed in several cancer types.
Our study has some limitations. First, it was retrospective in nature. Second, it did not include the localisa-
tion information of each marker and therefore did not provide data on the spatial distribution of immune cells. 
Furthermore, since most patients underwent oesophagectomy when the neoadjuvant concurrent chemoradiation 
data was published and incorporated into clinical practice, none of the patients received preoperative treatment43. 
Additionally, no patient underwent immunotherapy; thus, this study did not provide any data regarding the 
response to immune checkpoint modulators.
In conclusion, we demonstrated that a high frequency of CD3+ TILs and high ICOS expression on immune 
cells are related to a favourable prognosis in ESCC. Furthermore, TIM-3 expression in immune cells was asso-
ciated with poor prognosis in uni- and multivariate analyses. Our findings may help improve ESCC outcomes 
beyond the application of PD-1 blockade. These discoveries have important implications for using antibody ther-
apies in addition to the PD-1/PD-L1 signalling pathway, such as TIM-3, in ESCC.
Methods
Patients and tissue samples. The study population comprised ESCC patients who underwent radical 
surgical resection at Severance Hospital and Samsung Medical Center, Seoul, Korea between 1996 and 2012. 
The inclusion criteria were (1) surgically resected ESCC with a curative aim and (2) availability of tumour tissue. 
Clinicopathologic data were collected and reviewed. Tumours were re-classified based on the 7th edition of the 
AJCC TNM cancer staging system. Twelve subjects underwent oesophagectomy and were subsequently identi-
fied as having stage IV. The study was approved by the Institutional Review Board (IRB) of Severance Hospital 
and was conducted according to the ethical principles, guidelines, and relevant regulations. The IRB approved 
our research, and as the study was a retrospective review of subjects, the requirement for informed consent was 
waived.
Tissue microarray preparation and IHC. ESCC specimens were histologically reviewed by two 
experienced pathologists (Y.C. and S.S.). Haematoxylin- and eosin-stained sections from formalin-fixed 
paraffin-embedded tissues were reviewed to identify the invasive carcinoma area. The most densely viable carci-
noma areas were chosen as the representative areas (core – 3.0 mm). Tissue microarrays were constructed from 
these samples and assessed by immunohistochemical staining for PD-L1, PD-1, CD3, CD8, Foxp3 (forkhead box 
P3), ICOS, TIM-3, and LAG-3.
The following primary antibodies were used: PD-L1 (dilution 1:100; clone SP142; Ventana), PD-1 (dilution 
1:100; clone NAT105; Cell Marque, Rocklin, CA, USA), CD3 (dilution 1:200; LabVision, Fremont, CA, USA), 
CD8 (RTU; clone C8/144B; Dako, Glostrup, Denmark), Foxp3 (dilution 1:100; Abcam, Cambridge, UK), ICOS 
(clone SP98; dilution 1:50; Thermo Scientific, Rockford, IL, USA), TIM-3 (dilution 1:200; clone D5D5RTM; Cell 
Signaling), and LAG-3 (clone EPR4392(2); dilution 1:100; Abcam). The staining protocols were the same as pub-
lished previously44.
IHC scoring. Two well-experienced pathologists manually scored each IHC in the tissue microarray samples. 
PD-L1 expression on tumour and immune cells was analysed separately. Tumour cells showing any intensity 
of membranous and/or cytoplasmic staining were defined as having positive staining, and the proportion of 
PD-L1-positive tumour cells was estimated as the percentage of total tumour cells in the whole section. The 
pre-specified cut-off values at 1%, 5%, 10%, 10%, 25%, and 50% were established. The same method was applied 
to assess PD-L1 expression in immune cells. The expression was defined as high density for CD3, CD8, ICOS, 
Foxp3, LAG-3, and PD-1 when the expression level was above the median value per four high-power fields 
(4HPFs).
Statistical analysis. We investigated the association between various immune markers and clinical data 
using the chi-squared test or Fisher’s exact test. Survival was analysed by the Kaplan-Meier method with log-rank 
for categorical variables. Uni- and multivariate analyses for predicting recurrence and survival were performed 
using the Cox regression method for the following variables: age, sex, smoking status, stage, histology, location, 
and each immune marker status. RFS was defined from the time of surgery to initial relapse or death. OS was 
defined as the time from the surgery until death from any cause or the most recent follow-up. The cases for OS 
included cases that were still alive and cases whose causes of death were not related to oesophageal cancer. Living 
patients were censored at the time of the last follow-up. Spearman’s rank correlation test was used to assess the 
relationship among various immune markers. All statistical analyses were performed using SPSS version 23.0 
(SPSS, Chicago, IL). P < 0.05 was considered statistically significant by the Kaplan-Meier method.
1 0Scientific RepoRtS |         (2019) 9:20197  | https://doi.org/10.1038/s41598-019-56828-7
www.nature.com/scientificreportswww.nature.com/scientificreports/
Data availability
As per institutional policy, the datasets generated and analysed during the current study are publicly unavailable; 
however, they are available from the corresponding author upon reasonable request.
Received: 4 July 2019; Accepted: 4 December 2019;
Published: xx xx xxxx
References
 1. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2015. CA: a cancer journal for clinicians 65, 5–29 (2015).
 2. Chen, G., Wang, Z., Liu, X. Y. & Liu, F. Y. Recurrence pattern of squamous cell carcinoma in the middle thoracic esophagus after 
modified Ivor-Lewis esophagectomy. World journal of surgery 31, 1107–1114 (2007).
 3. Xu, G. et al. Prognosis and Progression of ESCC Patients with Perineural Invasion. Scientific reports 7, 43828 (2017).
 4. Rice, T. W., Ishwaran, H., Ferguson, M. K., Blackstone, E. H. & Goldstraw, P. Cancer of the Esophagus and Esophagogastric Junction: 
An Eighth Edition Staging Primer. Journal of thoracic oncology: official publication of the International Association for the Study of 
Lung Cancer 12, 36–42 (2017).
 5. Ni, L. & Dong, C. New checkpoints in cancer immunotherapy. Immunological reviews 276, 52–65 (2017).
 6. Chiavenna, S. M., Jaworski, J. P. & Vendrell, A. State of the art in anti-cancer mAbs. Journal of biomedical science 24, 15 (2017).
 7. Gong, J., Chehrazi-Raffle, A., Reddi, S. & Salgia, R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: 
a comprehensive review of registration trials and future considerations. Journal for immunotherapy of cancer 6, 8 (2018).
 8. Amatore, F., Gorvel, L. & Olive, D. Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy. Expert 
opinion on therapeutic targets 22, 343–351 (2018).
 9. Anderson, A. C., Joller, N. & Kuchroo, V. K. Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in 
Immune Regulation. Immunity 44, 989–1004 (2016).
 10. Anderson, A. C. Tim-3: an emerging target in the cancer immunotherapy landscape. Cancer immunology research 2, 393–398 
(2014).
 11. Hu-Lieskovan, S. & Ribas, A. New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 
Checkpoint Inhibitors as a Backbone. Cancer journal (Sudbury, Mass.) 23, 10–22 (2017).
 12. Day, D. et al. From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely. Clinical cancer research : 
an official journal of the American Association for Cancer Research 23, 4980–4991 (2017).
 13. Cancer Genome Atlas Research, N. et al. Integrated genomic characterization of oesophageal carcinoma. Nature 541, 169–175 
(2017).
 14. Anaya, J. OncoLnc: linking TCGA survival data to mRNAs, miRNAs, and lncRNAs. Peerj Computer Science 2, e67 (2016).
 15. Smit, J. K. et al. Prognostic factors and patterns of recurrence in esophageal cancer assert arguments for extended two-field 
transthoracic esophagectomy. American journal of surgery 200, 446–453 (2010).
 16. Doki, Y. et al. Association of the primary tumor location with the site of tumor recurrence after curative resection of thoracic 
esophageal carcinoma. World journal of surgery 29, 700–707 (2005).
 17. Doi, T. et al. Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced 
Esophageal Carcinoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 36, 61–67 (2018).
 18. Kudo, T. et al. Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial. The Lancet. 
Oncology 18, 631–639 (2017).
 19. Ott, P. A., Hodi, F. S., Kaufman, H. L., Wigginton, J. M. & Wolchok, J. D. Combination immunotherapy: a road map. Journal for 
immunotherapy of cancer 5, 16 (2017).
 20. Palmer, A. C. & Sorger, P. K. Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug 
Additivity or Synergy. Cell 171, 1678–1691 e1613 (2017).
 21. Sathyanarayanan, V. & Neelapu, S. S. Cancer immunotherapy: Strategies for personalization and combinatorial approaches. 
Molecular oncology 9, 2043–2053 (2015).
 22. Patel, S. P. & Kurzrock, R. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Molecular cancer therapeutics 14, 
847–856 (2015).
 23. Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. The New England journal of medicine 348, 
203–213 (2003).
 24. Sato, E. et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with 
favorable prognosis in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America 102, 
18538–18543 (2005).
 25. Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (New 
York, N.Y.) 313, 1960–1964 (2006).
 26. Chen, D. S. & Mellman, I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1–10 (2013).
 27. Gooden, M. J., de Bock, G. H., Leffers, N., Daemen, T. & Nijman, H. W. The prognostic influence of tumour-infiltrating lymphocytes 
in cancer: a systematic review with meta-analysis. British journal of cancer 105, 93–103 (2011).
 28. Matsumoto, H. et al. Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast 
cancer. Breast cancer research and treatment 156, 237–247 (2016).
 29. Lopez, M. et al. The role of regulatory T lymphocytes in the induced immune response mediated by biological vaccines. 
Immunobiology 211, 127–136 (2006).
 30. Yagi, T. et al. PD-L1 Expression, Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected 
Esophageal Cancer. Annals of surgery 269, 471–478 (2019).
 31. Jiang, D. et al. Tumour infiltrating lymphocytes correlate with improved survival in patients with esophageal squamous cell 
carcinoma. Scientific reports 7, 44823 (2017).
 32. Jesinghaus, M. et al. Increased intraepithelial CD3+ T-lymphocytes and high PD-L1 expression on tumor cells are associated with 
a favorable prognosis in esophageal squamous cell carcinoma and allow prognostic immunogenic subgrouping. Oncotarget 8, 
46756–46768 (2017).
 33. Zheng, X. et al. Prognostic Role of Tumor-Infiltrating Lymphocytes in Esophagus Cancer: a Meta-Analysis. Cellular physiology and 
biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology 45, 720–732 (2018).
 34. Sharpe, A. H. & Freeman, G. J. The B7-CD28 superfamily. Nature reviews. Immunology 2, 116–126 (2002).
 35. Wallin, J. J., Liang, L., Bakardjiev, A. & Sha, W. C. Enhancement of CD8+ T cell responses by ICOS/B7h costimulation. Journal of 
immunology (Baltimore, Md.: 1950) 167, 132–139 (2001).
 36. Hald, S. M. et al. LAG-3 in Non-Small-cell Lung Cancer: Expression in Primary Tumors and Metastatic Lymph Nodes Is Associated 
With Improved Survival. Clinical lung cancer 19, 249–259 e242 (2018).
 37. He, Y. et al. LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-
Infiltrating Lymphocytes. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 
12, 814–823 (2017).
1 1Scientific RepoRtS |         (2019) 9:20197  | https://doi.org/10.1038/s41598-019-56828-7
www.nature.com/scientificreportswww.nature.com/scientificreports/
 38. Zhang, Y. et al. Prognostic Value of Lymphocyte Activation Gene-3 (LAG-3) Expression in Esophageal Squamous Cell Carcinoma. 
Journal of Cancer 9, 4287–4293 (2018).
 39. Jiang, J. et al. Decreased galectin-9 and increased Tim-3 expression are related to poor prognosis in gastric cancer. PloS one 8, e81799 
(2013).
 40. Zhuang, X. et al. Ectopic expression of TIM-3 in lung cancers: a potential independent prognostic factor for patients with NSCLC. 
American journal of clinical pathology 137, 978–985 (2012).
 41. He, Y. et al. TIM-3, a promising target for cancer immunotherapy. OncoTargets and therapy 11, 7005–7009 (2018).
 42. Tsutsumi, S. et al. Programmed death-ligand 1 expression at tumor invasive front is associated with epithelial-mesenchymal 
transition and poor prognosis in esophageal squamous cell carcinoma. Cancer science 108, 1119–1127 (2017).
 43. van Hagen, P. et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. The New England journal of medicine 366, 
2074–2084 (2012).
 44. Kim, H. R. et al. PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer 
patients. Scientific reports 6, 36956 (2016).
Acknowledgements
This work was supported by a grant from the National research foundation (NRF), Republic of Korea 
(NRF-2017R1D1A1B03029874, NRF-2017M3A9E9072669, NRF-2019M3A9B6065231,  and NRF-
2016R1A5A2945889).
Author contributions
M.H.H., and S.S. were involved in manuscript preparation and editing. H.R.K. and Y.C. were involved in study 
concepts. Y.C., B.C.C. and H.R.K. were involved in study design. D.J.K., S.Y.P., S.K.S., S.E.L. and Y.C. were 
involved in data acquisition. S.S., Y.C., J.I. Zo. and Y.M.S. were involved in quality control of data and algorithms 
and data analysis and interpretation. M.H.H., S.S. and S.K.S. all contributed equally to the work and should be 
considered co-first authors. S.Y.P., Y.C. and H.R.K. contributed equally to this work as corresponding authors.
Competing interests
The authors declare no competing interests.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-019-56828-7.
Correspondence and requests for materials should be addressed to S.Y.P., Y.-L.C. or H.R.K.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
